RemeGen Co (HKSE:09995) Interest Expense : HK$-22.2 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. RemeGen Co's interest expense for the three months ended in Dec. 2023 was HK$ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-22.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. RemeGen Co's Operating Income for the three months ended in Dec. 2023 was HK$ 0.0 Mil. RemeGen Co's Interest Expense for the three months ended in Dec. 2023 was HK$ 0.0 Mil. GuruFocus does not calculate RemeGen Co's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RemeGen Co Interest Expense Historical Data

The historical data trend for RemeGen Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Interest Expense Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-48.73

-34.65

-6.52

-7.55

-25.26

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial									-3.77	-	-8.22	-	-13.97

RemeGen Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-22.2 Mil.

RemeGen Co (HKSE:09995) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RemeGen Co's Interest Expense for the three months ended in Dec. 2023 was HK$0.0 Mil. Its Operating Income for the three months ended in Dec. 2023 was HK$0.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was HK$1,001.1 Mil.

RemeGen Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate RemeGen Co's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines